Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06633757 · ClinicalTrials.gov registry record · Phase 1
Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance
A Phase 1 study of Primary Ciliary Dyskinesia (PCD), sponsored by ReCode Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT06633757 is a Phase 1 study of Primary Ciliary Dyskinesia (PCD) that is active but no longer recruiting, run by ReCode Therapeutics. The registered enrollment target is 12 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT06633757, a Phase 1 study of Primary Ciliary Dyskinesia (PCD), is active but no longer recruiting, sponsored by ReCode Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-dose study with RCT1100 and is designed to provide safety, tolerability and preliminary efficacy data for future clinical studies.
Conditions Studied
Interventions
- DRUG RCT1100
Study Locations (3)
North Carolina
- UNC - Chapel Hill
Other
- Copenhagen University Hospital - Rigshospitalet - Copenhagen
North Rhine-Westphalia
- Münster University Hospital, Albert-Schweitzer-Campus 1 - Münster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06633757
The ClinicalTrials.gov registry entry for NCT06633757 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ReCode Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Ciliary Dyskinesia (PCD) appearing as the primary indexed condition, and to 1 intervention - of which RCT1100 is the first listed.
NCT06633757 reports 3 study locations spanning 3 distinct geographic areas - top geographies include North Carolina, Other, North Rhine-Westphalia.
Frequently Asked Questions
What is clinical trial NCT06633757 about?
NCT06633757 is a clinical study titled "Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance". This is a multi-dose study with RCT1100 and is designed to provide safety, tolerability and preliminary efficacy data for future clinical studies.
What is the current status of trial NCT06633757?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-10-22. Estimated completion is 2025-12-30.
What conditions does trial NCT06633757 study?
This clinical trial studies the following conditions: Primary Ciliary Dyskinesia (PCD).
What interventions are being tested in trial NCT06633757?
The interventions under investigation include: RCT1100 (DRUG).
Who is sponsoring clinical trial NCT06633757?
This trial is sponsored by ReCode Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06633757 being conducted?
This trial has 3 study locations across North Carolina, North Rhine-Westphalia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.